Lucid Diagnostics Q3: EsoGuard rev $1.2M (+50% YoY), net loss $12.4M ($0.25/share), raises $21.75M via notes

Lucid Diagnostics Inc.

2024-Q3 EPS reported -$0.87 revenue$3,149,000

EsoGuard revenue $1.2M, up 20% sequentially from Q2 2024 and 50% YoY from Q3 2023.
GAAP net loss attributable to common stockholders $12.4M, or $(0.25) per share.
Non-GAAP adjusted loss $10.1M, or $(0.20) per share, excluding stock-based comp and other non-cash items.
Cash $14.5M at Sep 30, 2024; entered into $21.75M senior secured convertible notes to extend cash runway.
Performed 2,787 commercial EsoGuard tests in Q3; October record >1,400 tests; clinical validation study accepted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.